WO2001043733A3 - Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation - Google Patents

Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation Download PDF

Info

Publication number
WO2001043733A3
WO2001043733A3 PCT/US2000/033916 US0033916W WO0143733A3 WO 2001043733 A3 WO2001043733 A3 WO 2001043733A3 US 0033916 W US0033916 W US 0033916W WO 0143733 A3 WO0143733 A3 WO 0143733A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
inflammation
kits
inhibiting
Prior art date
Application number
PCT/US2000/033916
Other languages
French (fr)
Other versions
WO2001043733A2 (en
Inventor
Bruce H Levin
Original Assignee
Bruce H Levin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bruce H Levin filed Critical Bruce H Levin
Priority to AU21009/01A priority Critical patent/AU2100901A/en
Publication of WO2001043733A2 publication Critical patent/WO2001043733A2/en
Publication of WO2001043733A3 publication Critical patent/WO2001043733A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/075—Bulb type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Abstract

Methods, kits, apparatus, and compositions for inhibiting cephalic inflammation, including meningeal inflammation and cerebral inflammation for example, in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practising the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition if formulated for intranasal delivery. A kit comprising the composition and an intranasal applicator is also included in the invention. Apparatus for delivering or applying the compositions of the invention or for performing the methods of the invention are also described.
PCT/US2000/033916 1999-12-15 2000-12-15 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation WO2001043733A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21009/01A AU2100901A (en) 1999-12-15 2000-12-15 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17081799P 1999-12-15 1999-12-15
US60/170,817 1999-12-15

Publications (2)

Publication Number Publication Date
WO2001043733A2 WO2001043733A2 (en) 2001-06-21
WO2001043733A3 true WO2001043733A3 (en) 2002-05-10

Family

ID=22621377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033916 WO2001043733A2 (en) 1999-12-15 2000-12-15 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation

Country Status (2)

Country Link
AU (1) AU2100901A (en)
WO (1) WO2001043733A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7908000B2 (en) 2004-02-20 2011-03-15 Brainsgate Ltd. Transmucosal electrical stimulation
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6853858B2 (en) 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
GB0312844D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of compounds in medicine
DE10358749A1 (en) * 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Dosage form for combating primary headache
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
ITTO20110576A1 (en) 2011-06-30 2012-12-31 Medicam Health Science S R L COMPOSITION INCLUDING THE ASSOCIATION OF MELISSA PHYTO-EXTRACT, METHYLAMIDE AND A SOURCE OF NUCLEOTIDES AND / OR NUCLEOSIDES AND ITS USE IN THE TREATMENT OF HEADACHE AND HEMICRYANES
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
EP3093043B1 (en) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant and delivery system for neural stimulator
TR201604127A2 (en) * 2016-03-30 2016-08-22 Endemesis Ilac Sanayi Ve Ticaret Use of composition that contains local anesthetic for treating nausea
WO2024023676A1 (en) * 2022-07-28 2024-02-01 Cochlear Limited Techniques for providing stimulus for tinnitus therapy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754453A1 (en) * 1995-07-17 1997-01-22 Rainer K. Dr. Liedtke Local anesthetics for topical treatment of headache
BE1009851A3 (en) * 1996-01-11 1997-10-07 Thiebauld Charles Marie Pharmaceutical composition for the treatment of headaches and use of same
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
WO1998038998A1 (en) * 1997-03-03 1998-09-11 Darwin Discovery Limited The use of levobupivacaine or ropivacaine in treating migraine
WO1999003473A1 (en) * 1997-07-21 1999-01-28 Astra Aktiebolag Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
WO1999032103A1 (en) * 1997-12-19 1999-07-01 Astrazeneca Ab New use of local anaesthetics against vascular headaches
WO2000044432A1 (en) * 1999-01-27 2000-08-03 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cerebral neurovascular disorders and muscular headaches

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754453A1 (en) * 1995-07-17 1997-01-22 Rainer K. Dr. Liedtke Local anesthetics for topical treatment of headache
BE1009851A3 (en) * 1996-01-11 1997-10-07 Thiebauld Charles Marie Pharmaceutical composition for the treatment of headaches and use of same
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
WO1998038998A1 (en) * 1997-03-03 1998-09-11 Darwin Discovery Limited The use of levobupivacaine or ropivacaine in treating migraine
WO1999003473A1 (en) * 1997-07-21 1999-01-28 Astra Aktiebolag Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
WO1999032103A1 (en) * 1997-12-19 1999-07-01 Astrazeneca Ab New use of local anaesthetics against vascular headaches
WO2000044432A1 (en) * 1999-01-27 2000-08-03 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cerebral neurovascular disorders and muscular headaches

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"THE MERCK MANUAL", 1999, MERCK RESEARCH LABORATORIES, XP002181662 *
C.A. CAPUTI ET AL.: "Therapeutic Blockage of Greater Occipital and Supraorbital Nerves in Migraine Patients", HEADACHE, vol. 37, no. 3, 1997, pages 174 - 179, XP001036584 *
KUDROW L ET AL: "Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings", HEADACHE, AMERICAN ASSOCIATION FOR THE STUDY OF HEADACHE,, US, vol. 35, no. 2, 1 February 1995 (1995-02-01), pages 79 - 82, XP002086202, ISSN: 0017-8748 *
MAIZELS M ET AL: "Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial [see comments]", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 276, no. 4, 24 July 1996 (1996-07-24), pages 319 - 321, XP002086201, ISSN: 0098-7484 *
PAPPAGALLO, MARCO (1) ET AL: "Imaging neurogenic inflammation in patients with migraine headaches.", NEUROLOGY, (APRIL 12, 1999) VOL. 52, NO. 6 SUPPL. 2, PP. A274-A275. MEETING INFO.: 51ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY TORONTO, ONTARIO, CANADA APRIL 17-24, 1999 AMERICAN ACADEMY OF NEUROLOGY., XP001036585 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7908000B2 (en) 2004-02-20 2011-03-15 Brainsgate Ltd. Transmucosal electrical stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8954149B2 (en) 2004-02-20 2015-02-10 Brainsgate Ltd. External stimulation of the SPG
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation

Also Published As

Publication number Publication date
AU2100901A (en) 2001-06-25
WO2001043733A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
WO2001043733A3 (en) Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
AU7601998A (en) Composition and methods for transdermal delivery of acid labile drugs
AU4300701A (en) Methods and compositions for administration of therapeutic reagents
AU2003228436A1 (en) Method and apparatus for delivery of therapeutic agents
AU2001289820A1 (en) Novel pharmaceutical composition for administering n-0923
WO2001041807A3 (en) Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
AU2274201A (en) Compounds and compositions for delivering active agents
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1033998A4 (en) Method of suppressing beta-amyloid-related changes in alzheimer's disease
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
GT199700009AA (en) COMBINED THERAPY FOR OSTEOPOROSIS
WO1999021558A3 (en) Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
PL329940A1 (en) Compositions for once-a-day administration for use in treating diseases involving mediator effect of cyclooxygenase-2
AU1262501A (en) Compositions for transdermal and transmucosal administration of therapeutic agents
CA2454339A1 (en) Methods for preventing antipsychotic-induced weight gain
AU9547598A (en) Analgesic compositions
SE9603725D0 (en) New teatment
TR200000149T2 (en) Compositions for the prevention of cerebral neurovascular disorders, muscular headaches
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA01008993A (en) Combination treatment for depression and anxiety.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP